Drug intelligence / Profile preview

BAY 84-3174

Development stage: Unknown
Lead developer: Bayer
Modality: Small Molecules
Administration: Oral

Overview

BAY 84-3174 is an active metabolite of neladenoson bialanate (BAY 1067197), a prodrug developed by Bayer. Neladenoson bialanate is a potent and selective partial agonist of the adenosine A1 receptor, designed to provide cardioprotection without the unwanted side effects of full A1R agonists, such as bradycardia or atrioventricular blocks. It has been investigated for the oral treatment of chronic heart failure.

Targets

ADORA1 (Adenosine receptor A1 subtype)

Beyond the preview

Go deeper on BAY 84-3174.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BAY 84-3174.

Explore the full profile